Chronotherapy - Revision history

Lazy at 08:31, 18 January 2025

2025-01-18T08:31:08Z

← Older revision		Revision as of 01:31, 18 January 2025
Line 16:		Line 16:
	\|notes=Emerging evidence suggests that adjusting the timing of TMZ to morning administration could extend overall survival times for GBM patients, particularly those with MGMT methylated tumors. This approach aligns with the chronotherapy concept, which utilizes the body's circadian rhythms to optimize drug efficacy and minimize toxicity.		\|notes=Emerging evidence suggests that adjusting the timing of TMZ to morning administration could extend overall survival times for GBM patients, particularly those with MGMT methylated tumors. This approach aligns with the chronotherapy concept, which utilizes the body's circadian rhythms to optimize drug efficacy and minimize toxicity.
	\|links=https://medicine.wustl.edu/news/chemo-for-glioblastoma-may-work-better-in-morning-than-evening/, https://www.mdpi.com/2072-6694/13/11/2659		\|links=https://medicine.wustl.edu/news/chemo-for-glioblastoma-may-work-better-in-morning-than-evening/, https://www.mdpi.com/2072-6694/13/11/2659
	}}		\|overview=Chronotherapy with Temozolomide (TMZ) is an alternative chemotherapy treatment for glioblastoma multiforme (GBM) that has FDA approval and shows potential for improved survival rates, particularly in patients with MGMT methylated tumors when administered in the morning. Emerging evidence suggests that aligning TMZ administration with the body's circadian rhythms can enhance efficacy while managing side effects.}}

Lazy at 13:33, 25 December 2024

2024-12-25T13:33:42Z

← Older revision		Revision as of 06:33, 25 December 2024
Line 10:		Line 10:
	\|PFS_with=Improved in morning dosing, exact data still under investigation.		\|PFS_with=Improved in morning dosing, exact data still under investigation.
	\|usefulness_rating=4		\|usefulness_rating=4
			\|treatment_category=Alternative Chemotherapy
	\|usefulness_explanation=Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors.		\|usefulness_explanation=Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors.
	\|toxicity_level=Comparable to standard TMZ treatments, but timing affects management of side effects.		\|toxicity_level=Comparable to standard TMZ treatments, but timing affects management of side effects.

Lazy at 23:02, 15 May 2024

2024-05-15T23:02:52Z

← Older revision		Revision as of 16:02, 15 May 2024
Line 5:		Line 5:
	\|clinical_trial_phase=Research ongoing		\|clinical_trial_phase=Research ongoing
	\|common_side_effects=Increased side effects when administered in the morning; however, these are generally manageable with other therapies.		\|common_side_effects=Increased side effects when administered in the morning; however, these are generally manageable with other therapies.
	\|OS_without=~~Around~~ 19.5 months for patients with MGMT methylated tumors.		\|OS_without=13.5 months for general cases, 19.5 months for patients with MGMT methylated tumors.
	\|OS_with=~~Up to~~ 17 months for general cases, ~~and up to~~ 25.5 months for patients with MGMT methylated tumors when administered in the morning.		\|OS_with=17 months for general cases, 25.5 months for patients with MGMT methylated tumors when administered in the morning.
	\|PFS_without=Standard progression statistics for GBM.		\|PFS_without=Standard progression statistics for GBM.
	\|PFS_with=Improved in morning dosing, exact data still under investigation.		\|PFS_with=Improved in morning dosing, exact data still under investigation.

Lazy: Created page with "{{TreatmentInfo |drug_name=Chronotherapy with Temozolomide (TMZ) |FDA_approval=Yes (as part of standard glioblastoma treatment) |used_for=Glioblastoma Multiforme (GBM) |clinical_trial_phase=Research ongoing |common_side_effects=Increased side effects when administered in the morning; however, these are generally manageable with other therapies. |OS_without=Around 19.5 months for patients with MGMT methylated tumors. |OS_with=Up to 17 months for general cases, and up to 2..."

2024-05-15T23:01:14Z

Created page with "{{TreatmentInfo |drug_name=Chronotherapy with Temozolomide (TMZ) |FDA_approval=Yes (as part of standard glioblastoma treatment) |used_for=Glioblastoma Multiforme (GBM) |clinical_trial_phase=Research ongoing |common_side_effects=Increased side effects when administered in the morning; however, these are generally manageable with other therapies. |OS_without=Around 19.5 months for patients with MGMT methylated tumors. |OS_with=Up to 17 months for general cases, and up to 2..."

New page

{{TreatmentInfo
|drug_name=Chronotherapy with Temozolomide (TMZ)
|FDA_approval=Yes (as part of standard glioblastoma treatment)
|used_for=Glioblastoma Multiforme (GBM)
|clinical_trial_phase=Research ongoing
|common_side_effects=Increased side effects when administered in the morning; however, these are generally manageable with other therapies.
|OS_without=Around 19.5 months for patients with MGMT methylated tumors.
|OS_with=Up to 17 months for general cases, and up to 25.5 months for patients with MGMT methylated tumors when administered in the morning.
|PFS_without=Standard progression statistics for GBM.
|PFS_with=Improved in morning dosing, exact data still under investigation.
|usefulness_rating=4
|usefulness_explanation=Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors.
|toxicity_level=Comparable to standard TMZ treatments, but timing affects management of side effects.
|toxicity_explanation=Morning administration of TMZ shows potential for increased efficacy, with manageable increases in side effects.
|notes=Emerging evidence suggests that adjusting the timing of TMZ to morning administration could extend overall survival times for GBM patients, particularly those with MGMT methylated tumors. This approach aligns with the chronotherapy concept, which utilizes the body's circadian rhythms to optimize drug efficacy and minimize toxicity.
|links=https://medicine.wustl.edu/news/chemo-for-glioblastoma-may-work-better-in-morning-than-evening/, https://www.mdpi.com/2072-6694/13/11/2659
}}